The effect of oral contraception on cardiometabolic risk factors in women with elevated androgen levels

详细信息    查看全文

• 作者：Robert Krysiak^a ; ^{r.krysiak@interia.pl} ; Małgorzata Gilowska^a ; ^b ; Bogusław Okopień^a
• 关键词：DHEA-S ; dehydroepiandrosterone sulphate ; HDL ; high-density lipoprotein ; HMG-CoA ; 3-hydroxy-3-methyl-glutaryl-CoA ; HOMA1-IR ; the homeostatic model assessment 1 of insulin resistance ratio ; LDL ; low-density lipoprotein ; SD ; standard deviation ; SHBG ; sex hormone-binding globulin
• 刊名：Pharmacological Reports
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：69
• 期：1
• 页码：45-49
• 全文大小：281 K
• 卷排序：69

文摘

In unselected reproductive-aged women, use of combined estrogen-progestin oral contraceptive pills has been linked with an increased risk of vascular disease. The aim of this study was to investigate the effect of oral contraception on cardiometabolic risk factors in a population of women with hyperandrogenism.MethodsThe study included 16 untreated women with elevated testosterone levels and 15 matched healthy women who were then treated with oral contraceptive pills containing ethinyl estradiol (30 μg) and drospirenone (3 mg). Plasma lipids, glucose homeostasis markers, circulating levels of androgens, uric acid, high-sensitivity C-reactive protein (hsCRP), fibrinogen and homocysteine, as well as urinary albumin-to-creatinine ratio (UACR) were assessed at baseline and after 12 weeks of treatment.ResultsCompared to healthy women, women with elevated androgen levels showed increased plasma levels of hsCRP, fibrinogen and homocysteine, as well as a higher value of UACR. Oral contraception reduced androgen levels only in hyperandrogenic women. In healthy women, ethinyl estradiol plus drospirenone increased plasma levels of insulin, hsCRP, fibrinogen and homocysteine, while in women with elevated androgen levels their effect was limited only to a small increase in hsCRP.ConclusionsOur results suggest that a deteriorating effect of oral contraceptive pills containing ethinyl estradiol and drospirenone in hyperandrogenic women is weaker than in healthy young women and that ethinyl estradiol/drospirenone combination therapy may be safely used in the former group of patients.